Physician profile
Florin Stuleanu
NPI 1316958705
$583.87
in general payments reported to CMS, 2019-2025
15 companies · $27.77 in 2025
The $27.77 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $60.63 · 2021: $34.10 · 2022: $61.97 · 2023: $143 · 2024: $112 · 2025: $27.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $207 · Education: $75.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $207.05 |
| Education | $75.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $94.41 | 2019-2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $87.33 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $81.65 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $75.45 | 2023 | Dupixent |
| Baxter Healthcare | $54.13 | 2023-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Monarch Airway Clearance System |
| Glaxosmithkline, LLC. | $35.77 | 2022 | |
| Genzyme Corporation | $27.77 | 2025 | |
| Insmed, INC. | $21.74 | 2019 | |
| Genentech USA, INC. | $19.66 | 2019 | |
| Astellas Pharma US INC | $15.97 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.60 | 2023 | Ofev |
| Novartis Pharmaceuticals Corporation | $15.11 | 2019 | |
| Harmony Biosciences LLC | $13.70 | 2022 | |
| Philips North America LLC | $13.08 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Florin Stuleanu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.